Drug design and development company Isomorphic Labs has announced it has raised $600 million in its first external funding round.
Prosperity of the capital He led the round with participation from GV (Google Ventures) and existing investors alphabet.
What it does
Isomorphic Labs, released on Google DeepMind in 2021, We have announced the latest joint AI offering the Alphafold 3, an AI model developed by Isomorphic Labs and Google Deepmind.
The purpose of Alphafold 3 is to accurately predict the structure of proteins, DNA, RNA, and ligands and their interactions. The ligands are as follows: An ion or molecule is a molecule having a functional group that binds to a central metal atom to form a coordination complex.
The companies said they expect Alphafold 3 to help change their understanding of the biological world and drug discovery.
Since its launch, Isomorphic Labs has built an AI drug design engine that goes beyond the AlphaFold system, consisting of predictive, generative AI models with the ability to work in multiple therapeutic areas and drug modalities.
The company aims to use its funds to apply AI drug design engines to provide biomedical breakthroughs, and to promote drug design programs across multiple therapeutic areas and drug modalities.
“We are excited to bring together a group of leading investors with deep AI and life science expertise as we aim to transform this industry through an interdisciplinary approach,” Demis Hassabis, founder and CEO of Isomorphic Labs, said in a statement.
“This funding is an important step towards our mission to further turbocharge the development of the next generation of AI drug design engines, helping us move our own programs into clinical development, and to solve all diseases with the help of AI.”
Market Snapshot
In February, Isomorph Labs signed an agreement to expand strategic research collaboration with the drug giant Novartis. The agreement came in 2024 in the wake of previous cooperation between the two companies.
In the new agreement, Isolabs and Novartis expanded the scope of the initial collaboration, adding three additional research programs on the same financial terms as the original agreement.
Last year, Isomorph Lab launched a strategic research collaboration Eli Lilly and the company discover small molecule therapy drugs for multiple targets. Isomorphic received a $45 million advance cash payment.
The isomorphism also signed a strategic research collaboration with Novartis to discover small molecule therapy for three private targets.
Google DeepMind Alphaproteo has launched an AI system aimed at helping biological and health researchers design high-strength proteins in novels that target molecules with accuracy and strength.
Alphaproteo was trained with Protein Data Bank (PDB), which enables breakthroughs in science and education by providing access and tools for exploring, visualizing and analyzing experimentally determined 3D structures from PDB archives.
